Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective

por Gómez, Roberto E., Ardigo, Maria L.
Publicado 2012

NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines

por Fernandez, Luis E., Gabri, Mariano R., Guthmann, Marcelo D., Gomez, Roberto E., Gold, Silvia, Fainboim, Leonardo, Gomez, Daniel E., Alonso, Daniel F.
Publicado 2010

Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data

por Vázquez, Ana M., Hernández, Ana M., Macías, Amparo, Montero, Enrique, Gómez, Daniel E., Alonso, Daniel F., Gabri, Mariano R., Gómez, Roberto E.
Publicado 2012

A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients

por Weinberg, Ruth S, Grecco, Marcelo O, Ferro, Gimena S, Seigelshifer, Debora J, Perroni, Nancy V, Terrier, Francisco J, Sánchez-Luceros, Analía, Maronna, Esteban, Sánchez-Marull, Ricardo, Frahm, Isabel, Guthmann, Marcelo D, Di Leo, Daniela, Spitzer, Eduardo, Ciccia, Graciela N, Garona, Juan, Pifano, Marina, Torbidoni, Ana V, Gomez, Daniel E, Ripoll, Giselle V, Gomez, Roberto E, Demarco, Ignacio A, Alonso, Daniel F
Publicado 2015